New azaaurone derivatives as potential multitarget agents in HIV‐TB coinfection
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202300560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Debora I Leite und 10 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Tecnologia em Fármacos, Laboratório de Síntese de Fármacos (LASFAR), Fundação Oswaldo Cruz, Rio de Janeiro, Brasil. Hauptthemen laut MEDLINE: Coinfection, Tuberculosis, Mycobacterium tuberculosis, HIV Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Tuberculosis (TB) disease, caused by Mycobacterium tuberculosis ( Mtb ) is the leading cause of death among people with human immunodeficiency virus (HIV) infection. No dual‐target drug is currently being used to simultaneously treat both infections. This work aimed to obtain new multitarget HIV‐TB agents, with the goal of optimizing treatments and preventing this coinfection. These compounds incorporate the structural features of azaaurones as anti‐ Mtb and zidovudine (AZT) as the antiretroviral moiety. The azaaurone scaffold displayed submicromolar activities against Mtb , and AZT is a potent antiretroviral drug. Six derivatives were synthetically generated, and five were evaluated against both infective agents. Evaluations of anti‐HIV activity were carried out in HIV‐1‐infected MT‐4 cells and on endogenous HIV‐1 reverse transcriptase (RT) activity. The H37Rv strain was used for anti‐ Mtb assessments. Most compounds displayed potent antitubercular and moderate anti‐HIV activity. ( E )‐ 12 exhibited a promising multitarget profile with an MIC 90 of 2.82 µM and an IC 50 of 1.98 µM in HIV‐1‐infected T lymphocyte cells, with an 84% inhibition of RT activity. Therefore, ( E )‐ 12 could be the first promising compound from a family of multitarget agents used to treat HIV‐TB coinfection. In addition, the compound could offer a prototype for the development of new strategies in scientific research to treat this global health issue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Tecnologia em Fármacos, Laboratório de Síntese de Fármacos (LASFAR), Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
- Programa de Pós Graduação em Farmacologia e Química Medicinal (PPGFQM), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil.
- Molecular Mycobacteriology Research Unit, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
ORCID-Profile: Pedro A G Costa
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Leite, D. I., Campaniço, A., Costa, P. A. G., Correa, I. A., da Costa, L. J., Bastos, M. M., Moreira, R., Lopes, F., Jordaan, A., Warner, D. F., & Boechat, N. (2024). New azaaurone derivatives as potential multitarget agents in HIV‐TB coinfection. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300560
Vancouver
Leite DI, Campaniço A, Costa PAG, Correa IA, da Costa LJ, Bastos MM, et al. New azaaurone derivatives as potential multitarget agents in HIV‐TB coinfection. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300560
BibTeX
@article{Leite2024,
author = {Leite, Debora I and Campaniço, Andre and Costa, Pedro A G and Correa, Isadora A and da Costa, Luciana J and Bastos, Monica M and Moreira, Rui and Lopes, Francisca and Jordaan, Audrey and Warner, Digby F and Boechat, Nubia},
title = {New azaaurone derivatives as potential multitarget agents in HIV‐TB coinfection},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202300560}
}
EUVIMED